ストックスクリーナーアプリを入手
1.69
24.26%
0.33
アフターアワーズ：
1.68
-0.01
-0.59%
前日終値:
$1.36
開ける：
$1.42
24時間の取引高:
4.95M
Relative Volume:
2.62
時価総額：
$221.88M
収益：
-
当期純損益:
$-217.44M
株価収益率:
-0.7788
EPS:
-2.17
ネットキャッシュフロー:
$-205.20M
1週間 パフォーマンス:
+43.22%
1か月 パフォーマンス:
+27.07%
6か月 パフォーマンス:
-48.32%
1年 パフォーマンス:
-75.47%
1日の値動き範囲:
$1.40
$1.71
1週間の範囲:
$1.18
$1.71
52週間の値動き範囲:
$1.11
$8.1442
Prime Medicine Inc Stock (PRME) Company Profile
PRME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
1.69 | 165.43M | 0 | -217.44M | -205.20M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-05-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2024-04-22 | 開始されました | Chardan Capital Markets | Buy |
| 2024-04-08 | 開始されました | TD Cowen | Buy |
| 2024-04-03 | 開始されました | Wedbush | Outperform |
| 2024-01-16 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-10-09 | 開始されました | BMO Capital Markets | Outperform |
| 2023-07-31 | 開始されました | Guggenheim | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2022-11-14 | 開始されました | Goldman | Neutral |
| 2022-11-14 | 開始されました | JP Morgan | Overweight |
| 2022-11-14 | 開始されました | Jefferies | Buy |
| 2022-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prime Medicine Inc (PRME) 最新ニュース
Prime Medicine Elects Directors at Annual Meeting - TipRanks
Altria, Prime Medicine, US Steel, DLocal, Prothena: Trending by Analysts - TipRanks
Layoff Tracker: iTeos Winds Down Operations - BioSpace
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN
Prime Medicine Announces Key Presentations at Two Major Healthcare Investor Conferences in June - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Citigroup Downgrades Prime Medicine (PRME) Amid Significant Pric - GuruFocus
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges By Investing.com - Investing.com South Africa
Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Targ - GuruFocus
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Target | PRME Stock News - GuruFocus
Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks
Hold Rating for Prime Medicine, Inc. Amid Financial Uncertainties and Strategic Adjustments - TipRanks
Hold Rating on Prime Medicine, Inc. Amid Strategic Shifts and Financial Reevaluation - TipRanks
Prime Medicine Executives Make Bold Stock Purchases! - TipRanks
Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus
Prime Medicine Executives Make Significant Stock Purchases - TradingView
Prime Medicine CEO Acquires 125,000 Shares - TradingView
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish - MSN
Prime Medicine Cuts Workforce By 25% In Strategic Shift - Finimize
CEO among 25% of staff out the door at cash-strapped Prime - The Pharma Letter
Prime Medicine (PRME) Sees Price Target Adjustment by JMP Securities | PRME Stock News - GuruFocus
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Prime Medicine (PRME) Receives Downgrade from JP Morgan | PRME Stock News - GuruFocus
PRME: Prime Medicine Downgraded to Neutral by HC Wainwright & Co - GuruFocus
Prime Medicine downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Prime Medicine (PRME) Faces Downgrade Amid Strategic Shift | PRM - GuruFocus
Prime Medicine (PRME) Adjusts Strategy Amid Leadership Changes | - GuruFocus
Prime Medicine price target lowered to $6 from $10 at Citizens JMP - TipRanks
Prime Medicine, Inc.: Hold Rating Amid Strategic Restructuring and Long-term Uncertainty - TipRanks
Prime Medicine refocuses on liver disease, leadership changes By Investing.com - Investing.com South Africa
PRME Downgraded by JPMorgan Amid Strategic Shift | PRME Stock News - GuruFocus
Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits - Genetic Engineering and Biotechnology News
Prime Medicine downgraded to Neutral from Overweight at JPMorgan - TipRanks
Prime Medicine to deprioritize CGD programs, reduce headcount by 25% - TipRanks
6 Analysts Assess Prime Medicine: What You Need To Know - Benzinga
CRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staff - The Boston Globe
Jefferies cuts Prime Medicine stock target to $9, maintains Buy By Investing.com - Investing.com Canada
Chardan Lowers Price Target on Prime Medicine to $12 From $16, Keeps Buy Rating - marketscreener.com
David Liu gene-editing startup cuts staff, names new CEO - The Business Journals
PRME: Chardan Capital Adjusts Price Target for Prime Medicine | - GuruFocus
Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT Stock News - GuruFocus
Prime Medicine price target lowered to $12 from $16 at Chardan - TipRanks
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish By Stocktwits - Investing.com India
Wedbush Adjusts Prime Medicine Price Target to $8 From $13, Maintains Outperform Rating - marketscreener.com
Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot - BioPharma Dive
Prime Medicine CEO Keith Gottesdiener to step down, Allan Reine to succeed - TipRanks
Prime Medicine Prioritizes Pipeline, Cuts Workforce By 25%Stock Plunges - Nasdaq
Prime Medicine Inc (PRME) 財務データ
収益
当期純利益
現金流量
EPS
Prime Medicine Inc (PRME) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
0.00%
2.33%
大文字化:
|
ボリューム (24 時間):